BBOT
BridgeBio Oncology Therapeutics, Inc. (BBOT)
Market Closed
15 Dec, 20:00
NASDAQ (NMS) NASDAQ (NMS) Primary $
11. 98
-0.61
-4.85%
$
- Market Cap
- P/E Ratio
- Div Yield
117,407 Volume
- Eps
$ 12.59
Previous Close Day Range
11.8 12.73
Year Range
8.5 14.87
Want to track BBOT and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 57 days
BridgeBio Oncology Therapeutics: Promising KRAS Drug Developer - In My View, At Least
BridgeBio Oncology Therapeutics (BBOT) targets KRAS and PI3Ka malignancies with next-generation small molecule therapeutics, aiming to surpass current market leaders. BBOT's lead candidate, BBO-8520, demonstrated a strong overall response rate in early Phase 1a data for KRAS G12C NSCLC, with no Grade 2+ adverse events. All three BBOT pipeline candidates are expected to report Phase 1 data in 2026, positioning the company for key clinical catalysts.
Seekingalpha | 3 days ago
2025 © Marketlog. All Rights Reserved.
